Kornimate/medical-research-clean huggingface dataset:
effects of sitagliptin on gastric emptying in healthy subjects

Conditions: Gastroparesis; Diabetes Mellitus

Summary: the purpose of this study is to determine the effects of the drug, sitagliptin, on the rate at which the stomach empties, and the release of gut hormones and blood glucose concentrations, after a mashed potato meal in healthy subjects. sitagliptin has been shown to reduce the blood glucose (sugar) response to a meal and this may potentially be due to slowing of stomach emptying. this is particularly relevant to people who have diabetes, in whom normalization of elevated blood glucose levels is important to maintain health.

the purpose of this study is to evaluate the effect of sitagliptin on gastric emptying, intragastric meal distribution, postprandial glycemia and insulinemia in healthy subjects. glucagon-like peptide-1 (glp-1) inhibits gastric emptying, thereby slowing the delivery of nutrients, and their absorption, across the small intestine. the rate of entry of carbohydrate into the small intestine is especially important in patients with diabetes mellitus. sitagliptin is an orally administered inhibitor of dipeptidyl-peptidase-iv (dpp-iv), the enzyme responsible for the degradation of glp-1. it is hypothesized that sitagliptin will increase the glp-1 response to, and thereby slow gastric emptying and diminish the glycemic response to, a carbohydrate-containing meal. fifteen healthy subjects (male and female) will be studied. each subject will be studied on two occasions following treatment for 2 days with sitagliptin (100mg once daily) or matching placebo in a randomized, double blind, crossover design. measurements of gastric emptying, intragastric meal distribution, blood glucose concentrations, gut hormones and appetite will be measured for 4 hours following ingestion of a mashed potato meal.

Eligibility criteria:
inclusion criteria: * male or female (females must be using an appropriate contraceptive method) * 18 - 45 years * body mass index (bmi) 19 - 25 kg/m2. exclusion criteria: * subjects with gastrointestinal disease, history of gastrointestinal surgery and/or significant gastrointestinal symptoms * subjects taking medication known to influence gastrointestinal function * alcohol intake \> 20 g per day * smoking \> 10 cigarettes per day * pregnant and/or lactating females * calculated creatinine clearance \< 60 ml/min * exposure to ionising radiation for research purposes in the previous 12 months.

Keywords: gastric emptying glycemia appetite incretin hormones
analysis of circulating tumor dna (ctdna) in her2-low advanced/metastatic breast cancer

Conditions: Advanced Metastatic Breast Cancer

Summary: a pilot study on circulating tumor dna (ctdna) in advanced/metastatic breast cancer with low levels of her2 expression (her2 low)

prospective single-center feasibility study of 30 patients with carcinoma breast with low levels of her2 expression, defined as 1+ or 2+ expression levels by the ihc technique (immunohistochemistry) and the gene not amplified by the ish test (in situ hybridization)

Eligibility criteria:
inclusion criteria * participants diagnosed with her2-low breast cancer, defined as ihc score 1+ or 2+ and not amplified at in situ hybridization (ish) test as confirmed by local laboratory testing. * participants should be at advanced or metastatic setting prior to treatment. * written informed consent (accordo di partecipazione alla ricerca scientifica) and specific informed consent to the study must be signed and dated by the patient and the doctor prior to inclusion. * patients must be accessible for follow-up.
cavitation ultrasound in treatment of patients with pcos

Conditions: PCOS

Summary: the aim of the current work was to compare the efficacy of cavitation ultrasound, metformin or combination of both in obese women with polycystic ovary syndrome (pcos) regarding clinical pregnancy rate, ovulation rate, insulin resistance, serum testosterone level, lipid profile.

polycystic ovary syndrome (pcos) affects 5 to 10% of women of childbearing age and is the most common cause of anovulatory infertility. common clinical manifestations include menstrual irregularities and signs of androgen excess such as hirsutism, acne, and alopecia. metformin, a biguanide, is the most widely used drug for the treatment of type 2 diabetes worldwide. its primary action is to inhibit hepatic glucose production, but it also increases the sensitivity of peripheral tissues to insulin. the increase in insulin sensitivity, which contributes to the efficacy of metformin in the treatment of diabetes, has also been shown in non diabetic women with the polycystic ovary syndrome.in women with pcos, long-term treatment with metformin may increase ovulation, improve menstrual cyclicity, and reduce serum androgen levels; the use of metformin may also improve hirsutism. if published data on the effects of metformin in the prevention of diabetes can be extrapolated to women with the pcos, then the drug may actually retard progression to glucose intolerance in affected women, as reported in a small, retrospective study. ultrasonic vibrations spread in the form of a wave in medium such as a liquid or a solid. when the particles of an elastic medium are under ultrasonic vibration, they act continuously in only one direction. the lipolytic range of ultrasounds is 30-70 kilohertz (khz), and the best effects are obtained in a range between30-35 khz. the depth of the treatment in the tissues is generally2-3 cm, to avoid muscles involvement. biological effects of ultrasounds on adipocytes are: micro-mechanical, thermal, micro-streaming and cavitation. cavitation ultrasound means that ultrasounds produce an alternation of decompression and compression waves in a fluid media which progressively increase the tension of the adipocyte until it implodes and frees the emulsified fat. the aim of the current work was to compare the efficacy of cavitation ultrasound, metformin or combination of both in obese women with polycystic ovary syndrome (pcos) regarding clinical pregnancy rate, ovulation rate, insulin resistance, serum testosterone level, lipid profile.

Eligibility criteria:
inclusion criteria: * obese infertile polycystic ovarian syndrome (pcos) women exclusion criteria: * women 40 years or older * women using fertility treatments, oral contraceptives or other confounding medications during the last 3 months * smokers or with history of general diseases like cardiovascular, liver, kidney or respiratory disease, diabetes, uncontrolled hypertension, or malignancy
electromuscular stimulation therapy as a prophylactic method to reduce thromboses related to picc catheters in patients hospitalized in critical care units.

Conditions: Thrombosis; Catheter, Infusion Catheter (Vascular)

Summary: introduction: the placement of a peripheral inserted central catheter (picc) is a common practice in the hospital setting. however, despite all the advances reported, venous devices are not free of complications and catheter-related thrombosis (crt), being one of the most prevalent. electro muscular stimulation therapy can be a measure for the prevention of crt. objective: to know the efficacy of electro muscular stimulation therapy in patients hospitalized in critical care units to prevent venous thrombosis related to picc catheters. methodology: a multicenter randomized clinical trial (rct) will be carried out at the dr. josep trueta university hospital in girona, hospital del mar in barcelona, althaia foundation in manresa. with a total of 68 patients with picc catheters in critical care units, they will be randomly assigned to the intervention group (n=34) to whom, in addition to the usual protocolized care related to the vascular catheter, will be applied e eco-ems protocol, or the control group (n=34) to which only the usual protocolized care related to the vascular catheter was applied. intervention: it will consist of the application of electrostimulation therapy five days a week, two daily sessions of 20 minutes in the intervention group. both groups underwent five ultrasound examinations after the placement of the picc to determine the appearance of crt. expected results: it is expected to observe that the application of the eco-ems protocol reduces thrombosis in the patients of the intervention group, compared to those of the control group.


Eligibility criteria:
inclusion criteria: * patients admitted to the critical unit with a picc whose insertion is done by the eiav of the same hospital. * patients between 18 and 80 years of age. * treatments related to the device protocolized by the same hospital as the eiav implanter. exclusion criteria: * patients who do not sign informed consent. * patients with pacemakers and/or implantable automatic defibrillators. * patients with epilepsy. * removal of the device within the first 15 days after insertion. * hospital discharge, transfer to another hospital or death lethalis during the duration of the study. * displacement of the tip of the catheter outside the lower ⅓ of the superior vein cava during the study period. * presence of lesions in the place where the electrodes must be placed to perform the electrostimulation therapy. * non-compliance with catheter monitoring: of the five ultrasound controls protocolized in the study, 80% were not complied with.
female asian nonsmoker screening study

Conditions: Lung Cancer

Summary: the study team propose to develop a database and biorepository of asian female never smokers. this population is at increased risk for developing lung cancer but do not meet current lung cancer screening criteria. study procedures will include up to 3 low-dose ct (ldct) scans and a blood-based assay with the capability for early detection of cancer. clinical, demographic and exposure history including possible wtc exposure will also be collected.


Eligibility criteria:
inclusion criteria: * age 40-74 years * female * never smoker defined as a lifetime exposure of less than 100 cigarettes * identify as from asian descent, defined as having reported ancestry or race from the continent of asia. individuals with mixed heritage are eligible. exclusion criteria: * prior history of lung cancer. * treatment for, or advisement by a physician of evidence of any cancer within the past five years, with the exceptions of non-melanoma skin cancer and most in-situ carcinomas based on pi discretion. (treatment for, or evidence of, melanoma or in-situ bladder/transition cell carcinomas within the preceding five years renders the potential participant ineligible.) * participation in a cancer prevention trial. * present symptoms suggestive of current lung cancer, including: unexplained weight loss of over 15 pounds within the 12 months or unexplained hemoptysis. * medical or psychiatric condition precluding informed medical consent. * pneumonia or acute respiratory infection within 12 weeks of enrollment that was treated with antibiotics under physician supervision.
kinectics of distribution of doxorubicin-lipiodol emulsion in c-tace

Conditions: Hepato Cellular Carcinoma

Summary: conventional transarterial chemoembolization with doxorubicin (c-tace) is the gold standard treatment for hepato cellular carcinoma (hcc) stage b (bclc) / stages a and b (child-pugh). clinical recommendations for ctace indicate that the doxorubicin solution may be reconstituted in either aqueous solution or iso-osmolar ionic iodinated contrast media. there is no consensus on which solvent should be used. hence, the clinical evaluation of lipiodol ctace would benefit from a standardization in the reconstitution of the drug. in this study, the comparison of the kinetics of distribution of the drug within the tumor micro-environment is expected to allow for comparison of drug solvents. this pilot study aims at evaluating the kinetics of distribution of the drug within the tumor micro-environment, for the two main solvents used in reconstituting the drug, namely normal saline and contrast media. the kinetics of distribution in the tumor will be evaluated primarily through regular biopsy sampling, and secondary with confocal laser endomicroscopy.


Eligibility criteria:
inclusion criteria: * adult (\>18) * informed consent * chc child-pugh stage a or b, bclc stage b * referred for chemoembolization of a non-surgery-candidate chc * blood test results compatible with ctace (inr ≤ 1,5, asat/alat\ 2,5g/dl) exclusion criteria: * contraindication to ctace, angiography, confocal laser endomicroscopy or liver biopsy hyperthyroidism * contraindication to the use of fluorescein, ariblastine,lipiodol, visipaque, gelita spon, avitene * extra hepatic metastasis * subcapsular or exophytic tumor impeding direct percutaneous access through healthy liver tissue * waiting list for liver transplant * complete portal venous thrombosis or flow inversion * pregnancy or breast feeding * protected major (guardianship) * patient in situation of exclusion (determined by a previous or ongoing study) * subject incapacity to understand informed consent

Keywords: conventional transarterial chemoembolization (c-tace) doxorubicin kinetics of distribution
correlation between idiopathic parkinson's disease and diabetes mellitus

Conditions: Observation

Summary: correlation between idiopathic parkinson's disease and diabetes mellitus in egyptian elderly patients

1. record rbdsq ("rapid eye movement sleep" behavior disorder screening questionnaire) total score difference between group 1 and group 2 . 2. oral glucose tolerance test will be performed and compared between group 3 and group 4. 3. association between glucose level and motor complication of l-dopa among idiopathic parkinson's patients using unified parkinson's disease rating scale (udprs).

Eligibility criteria:
inclusion criteria: 1. diabetic patients 2. idiopathic parkinsonism exclusion criteria: 1. secondary parkinsonism due to stroke, trauma and encephalitis. 2. drug induced parkinsonism.
vienna vascular liver disease study

Conditions: Vascular Liver Disease; Portal Vein Thrombosis; Budd-Chiari Syndrome; Non-Cirrhotic Portal Hypertension; Rendu Osler Weber; Cardiac Cirrhosis; Porto-sinusoidal Vascular Disorder

Summary: the aim of this register trial is to systematically study the epidemiology, risk factors, liver function as well prognosis of patients with vascular liver diseases. furthermore, important clinical parameters will be assessed in order to evaluate patients' coagulation status and in order to develop new biomarkers derived from blood, urine, stool or ascites of patients as well as histological samples from the upper / lower gi-tract or the liver in order to better understand the natural history of vascular liver diseases.

we will include patients with vascular liver diseases, including * portal vein thrombosis (pvt) * budd-chiari syndrome (bcs) * heredetary hemorrhagic teleangiectasia (hht, or osler-rendu disease) * noncirrhotic-portal hypertension (ncph) and porto-sinusoidal vascular disorder * cirrhosis cardiaque if the fulfill inclusion/exclusion criteria and provide written informed consent. participation in the biobank is optional for the patients. in particular, we will study the natural course of the patients in regard to hepatic decompensation (ascites, variceal bleeding, hepatic encephalopathy), need for intensified treatment (tips, icu, liver transplantation) and survival.

Eligibility criteria:
inclusion criteria: * diagnosis of a vascular liver disease by imaging (sonography, ct, mri), transient elastography or liver histology * pvt: portal vein thrombosis * ncph: non-cirrhotic portal hypertension * psvd: porto-sinusoidal vascular disorder * bcs: budd-chiari-syndrome * sos: sinusoidal occlusive disease * hht: hereditary hemorrhagic teleangiectasia * circad: cirrhosis cardiaque * age \>18 years and \<100 years * written informed consent obtained exclusion criteria: - withdrawal of written informed consent
anodal transcranial direct current stimulation of the visual cortex versus sham stimulation in the episodic migraine

Conditions: Sporadic Migraine

Summary: anodal tdcs increases the excitability of the cerebral cortex and its daily application during intercritical phase, may have a therapeutic effect in episodic migraine.

during the interictal phase, the cerebral cortex is characterised by hyperresponsiveness to repeated sensory stimuli, manifested by a lack of habituation or adaptation of cortical evoked responses. such habituation deficit can be shown in the visual cortex by the study of visual evoked potentials (vep) and it is possibly explained by a reduction in the cortical pre-activation level due to thalamo-cortical dysrhythmia. in healthy subjects and in migraineurs between attacks, anodal tdcs increases vep habituation and 1st block amplitude. in a proof-of-concept trial, the investigators have shown in 10 episodic migraine without aura patients that 2 weekly 15-minute sessions for 8 weeks of anodal tdcs over the visual cortex significantly decreased attack frequency, migraine days, attack duration and acute medication intake for more than 4 weeks after the last treatment session. this randomized trial was designed to prove the preventive effect in episodic migraine of anodal tdcs over the visual cortex compared to sham stimulation.

Eligibility criteria:
inclusion criteria: * diagnosis of episodic migraine with (ichd iii beta 1.2.1) or without aura (ichd iii beta 1.1) exclusion criteria: * preventive treatment * others diseases or contraindications to tdcs (epilepsy, pacemaker, metal prosthetics)
daily disposable performance of 1•day acuvue® trueye™ and 1•day acuvue® moist® with lacreon® technology

Conditions: Myopia; Hyperopia

Summary: this study is an observational registry of patients who have recently been prescribed 1•day acuvue® trueye® or 1•day acuvue® moist® brand contact lenses with lacreon® technology.


Eligibility criteria:
inclusion criteria: * wearers of 1•day acuvue® trueye™ or 1•day acuvue® moist® daily disposable soft contact lenses in both eyes aged \>8 years of age who have recently begun use of that lens type and have purchased at least 3 month supply of lenses. * the registrant must read and sign the informed consent form. minor subjects must obtain parental signature of informed consent and also sign an informed assent form. * the registrant must sign the release of medical records in the event of an adverse event in the study. * the registrant must appear able and willing to adhere to the instructions set forth in this clinical protocol. exclusion criteria: * previously wearing the type of lenses with which they are registering (1•day acuvue® trueye™ or 1•day acuvue® moist® daily disposable lenses). * current participant in an unrelated research study. * employee or family member of recruiting practitioner or johnson \& johnson.

Keywords: adverse events
molecular subtyping for prognosis evaluation in resected pancreatic adenocarcinoma

Conditions: Pancreatic Cancer Resectable

Summary: pancreatic adenocarcinoma (paad) patients following surgeries are prone to relapse shortly, while it is not well understood by current biomarkers. given the potential associations of human leukocyte antigen class i (hla-i) genotype with oncogenic mutational profile and immunotherapy efficacy, we aimed to assess whether differential hla-i genotype could predict the postoperative outcomes in resected paad patients.


Eligibility criteria:
inclusion criteria: * radically resected pancreatic adenocarcinoma (stage i-iii) * resected tumor tissues and matched blood cells available * signed informed consent exclusion criteria: * pancreatic cancer except pancreatic adenocarcinoma * non-radical resection

Keywords: human leukocyte antigen class i supertypes recurrence
effects of l-citrulline supplementation on vascular function in metabolic syndrome

Conditions: Metabolic Syndrome; Menopause

Summary: the objective of this project is to provide evidence that l-citrulline (cit) supplementation can improve vascular function in the fasted and acute hyperglycemia conditions in middle-aged and older women with metabolic syndrome.

using a double-blind, randomized, placebo-controlled, and parallel design, middle-aged and older women with metabolic syndrome will be randomized into receiving either cit supplementation (10g/day) or placebo (microcrystalline cellulose) for 4 weeks. the first visit will be approximately 1hr and 30 minutes. the 2nd and 3rd visits will each be approximately 2hrs and 30 minutes, separated by 4 weeks in between each visit. during visits 2 and 3, vascular measurements will be assessed in the fasted state and 30, 60, and 90 minutes after acute glucose ingestion (75g).

Eligibility criteria:
inclusion criteria: must present at least 3 of the following 5 cardiometabolic risk factors * waist circumference ≥88 cm * fasting glucose between 100-125 mg/dl or hba1c between 5.7-6.4%. * blood pressure ≥130 mm hg * triglyceride ≥ 150 mg/dl * hdl \<50 mg/dl the following are also inclusion criteria's: * women aged 45-79 years old * body mass index ≤ 39.9 kg/m2 * sedentary (defined as \< 120 min/week of exercise) * abstain from any dietary supplements with vascular effects for one month prior to the beginning of the study and until participation in study has terminated. exclusion criteria: * \ 79 years of age * use of medications and/or any supplements that may affect outcome variables (such as arginine-containing supplements, nitroglycerin, statin drugs, biguanides, insulin, beta blockers, statins, verapamil) * systolic blood pressure ≥ 160 mmhg * bmi \> 40 kg/m2 * recent changes in medication (3 months) * current smoking any tobacco use * cardiovascular disease, diabetes (type 1 or 2), and other metabolic or chronic diseases * more than 7 alcoholic drinks/week of consumption

Keywords: endothelial function aortic hemodynamics blood pressure obesity hypertension